INmune Bio expands partnership with Anthony Nolan for CORDStrom platform
INmune Bio and Anthony Nolan signed an amended and restated Material Transfer and License Agreement, effective April 29, 2026. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue for INmune Bio’s CORDStrom™ platform, an advanced Mesenchymal Stromal Cell (MSC) technology. The partnership aims to solve MSC consistency challenges by utilizing pooled and screened umbilical cord-derived MSCs, ensuring reproducibility and regulatory compliance. The collaboration will initially focus on developing treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), CORDStrom-col7a, CORDStrom-TRAIL for oncology, and inflammatory and degenerative diseases like Osteoarthritis and Systemic Lupus Erythematosus (SLE).
Key Highlights
- INmune Bio and Anthony Nolan signed an amended Material Transfer and License Agreement.
- Agreement, effective April 29, 2026, secures long-term umbilical cord tissue supply.
- Powers INmune Bio's CORDStrom™ platform for consistent, scalable cellular therapies.
- Initial focus on Recessive Dystrophic Epidermolysis Bullosa (RDEB) and CORDStrom-col7a.
- CORDStrom-TRAIL (Oncology) targets solid tumors; also for Osteoarthritis and SLE.
- Ensures regulatory compliance with FDA, EMA, MHRA, GMP, and HTA standards.